International Companies

Moderna bets big on RSV vaccine as full-year guidance unchanged

By Benjamin Chiou

Date: Thursday 02 May 2024

(Sharecast News) - Moderna saw its share price surge on Thursday after posting a smaller-than-expected quarterly loss as the Covid vaccine maker sets its sights on regulatory approvals of its second product later in the year.
The pharma group, whose only commercial product to date was the Covid vaccine known as...

Sign up for free or to read the full story

Email this article to a friend

or share it with one of these popular networks:


Article Archive

Top of Page